J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28085. Online ahead of print.
ABSTRACT
OBJECTIVES: To summarize the clinical characteristics and explore the role of treatment types in outcomes among psoriasis patients with Coronavirus Disease 2019 (COVID-19).
METHODS: The principal summary measures used were pooled prevalence and risk ratio (RR) with 95% confidential interval (CI). R statistic software was used for all the analysis.
RESULTS: A total of 19 studies including 4073 psoriasis patients with COVID-19 were eligible for the meta-analysis. The overall hospitalization rate is about 20.2% (95% CI, 12.7% – 28.7%), and changed to be 18.0 (95% CI, 9.9% – 27.6%) or 14.1 (95% CI, 5.9% – 24.6%) after systemic or biologic treatment. Moreover, the overall fatality rate is 1.5% (95% CI, 0.4% – 3.0%), and turned to be 0.7 (95% CI, 0 – 2.0%) or 0.5 (95% CI, 0 – 2.2%) after systemic or biologic therapy. Notably, a lower hospitalization risk ratio was found in patients receiving biologic therapy than those receiving other treatments (RR = 0.62, 95%CI, 0.42-0.94). The results were consistent after sensitivity analysis and trim-and-fill analysis.
CONCLUSIONS: Systemic, especially biologic therapy could lessen the clinical severity in psoriasis patients with COVID-19. Our finding will help to guide current recommendations and provide a reference for clinical decision-making. This article is protected by copyright. All rights reserved.
PMID:36000295 | DOI:10.1002/jmv.28085
